Abstract:The potential estrogenic activities of perfluoroalkyl substances (PFASs) are controversial. Here, we investigated the estrogenic/antiestrogenic activities of PFASs and explored the corresponding interaction mode of PFASs with the estrogen receptor (ER) by combining in vitro assays and in silico modeling. We found that three PFASs (perfluorobutanoic acid, perfluorobutane sulfonate, and perfluoropentanoic acid) exerted antiestrogenic effects by inhibiting luciferase activity, whereas perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) exerted estrogenic effects by inducing luciferase activity. When coexposed to 17β-estradiol (E2), all tested PFASs attenuated the E2-stimulated luciferase activity; unexpectedly, each PFAS could further attenuate the luciferase activity generated by the cotreatment with ICI 182,780 and E2, with a minimal effective concentration comparable to that found in human serum. PFHxS and PFOS significantly induced the gene expression of TFF1; additionally, all PFASs inhibited the E2-induced gene expression of TFF1 and EGR3. Furthermore, the results of the blind docking analyses suggested that the interaction with the coactivator-binding region on the ER surface should be included as a pathway through which PFASs exert estrogenic and antiestrogenic activities. Finally, we revealed the critical molecular property of the zero-order molecular connectivity index (MCI) (0χ) that affects the antiestrogenic activity of PFASs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.est.0c03468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.0c03468</a>.Structures of tested chemicals (Table S1); concentrations of PFASs in exposure solutions (Table S2); binding free energy components of E2 and PFOS in the ER–E2–PFOS complex (Table S3); compounds, parameters, and activity data (Table S4); RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) (part 1); in silico computational model (part 2); concentration–response luciferase activity of PFASs that gave a minor response in the MVLN assay (Figure S1); ERE-luciferase assay of PFASs in MVLN cells after cotreatment with E2 and ICI 182,780 (Figure S2); binding modes of 10 PFASs molecules in HIP molecular modeling (Figure S3); binding modes of 10 PFASs molecules in HIE molecular modeling (Figure S4); RMSD changes in MD simulations (Figure S5); and empirical distribution of R2* for the pEC50 model (Figure S6) (<a class="ext-link" href="/doi/suppl/10.1021/acs.est.0c03468/suppl_file/es0c03468_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Inhibition of human sulfotransferases (SULTs) by per- and polyfluoroalkyl substances (PFASs) and structure-activity relationship

Per- and polyfluoroalkyl substances inhibit human and rat 17β-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis

Carbon-chain length determines the binding affinity and inhibitory strength of per- and polyfluoroalkyl substances on human and rat steroid 5α-reductase 1 activity

Per- and polyfluoroalkyl substances exert strong inhibition towards human carboxylesterases

Inhibition of hydroxylated polychlorinated biphenyls (OH-PCBs) on sulfotransferases (SULTs)

An integrated assessment of ecological and human health risks of per- and polyfluoroalkyl substances through toxicity prediction approaches

Effects of Perfluoroalkyl Substances on Soil Respiration and Enzymatic Activity: Differences in Carbon Chain-Length Dependence

In vitro screening of understudied PFAS with a focus on lipid metabolism disruption

Transcriptomic re-analyses of human hepatocyte spheroids treated with PFAS reveals chain length and dose-dependent modes of action

Evaluation of the Estrogenic/Antiestrogenic Activities of Perfluoroalkyl Substances and Their Interactions with the Human Estrogen Receptor by Combining In Vitro Assays and In Silico Modeling

Dissect the association between per- and polyfluoroalkyl substances (PFAS) and kidney function from the perspective of lipid molecules

The oral acute toxicity of per- and polyfluoroalkyl compounds (PFASs) to Rat and Mouse: A mechanistic interpretation and prioritization analysis of untested PFASs by QSAR, q-RASAR and interspecies modelling methods

Overall and individual associations between per- and polyfluoroalkyl substances and liver function indices and the metabolic mechanism

Regulating the absorption and excretion of perfluorooctane sulfonate and its alternatives through influencing enterohepatic circulation

Insight into the binding model of per- and polyfluoroalkyl substances to proteins and membranes

Non-target discovery and risk prediction of per- and polyfluoroalkyl substances (PFAS) and transformation products in wastewater treatment systems

Perfluoroalkyl Substances (pfass) Influence the Structure and Function of Soil Bacterial Community: Greenhouse Experiment

Toxicity of Per- and Polyfluoroalkyl Substances to Aquatic Invertebrates, Planktons, and Microorganisms

Effects of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonic Acid (PFOS) on Soil Microbial Community

Perfluoroalkyl substances and immunotoxicity: An in vitro structure-activity relationship study in THP-1-derived monocytes and macrophages

Per- and Polyfluoroalkyl Substances (PFASs) Impair Lipid Metabolism in Rana nigromaculata: A Field Investigation and Laboratory Study